{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:47:51Z","timestamp":1782409671402,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10147-026-03030-1","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T01:48:19Z","timestamp":1776044899000},"page":"1236-1244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and\/or bridging therapy in relapsed\/refractory primary mediastinal large B-cell lymphoma"],"prefix":"10.1007","volume":"31","author":[{"given":"Risa","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-8088","authenticated-orcid":false,"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiteru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Aruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"3030_CR1","doi-asserted-by":"publisher","first-page":"e865","DOI":"10.1016\/j.clml.2021.06.012","volume":"21","author":"Z Ahmed","year":"2021","unstructured":"Ahmed Z, Afridi SS, Shahid Z et al (2021) Primary mediastinal B-cell lymphoma: a 2021 update on genetics, diagnosis, and novel therapeutics. Clin Lymphoma Myeloma Leuk 21:e865\u2013e875. https:\/\/doi.org\/10.1016\/j.clml.2021.06.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3030_CR2","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1182\/bloodadvances.2021004778","volume":"5","author":"V Camus","year":"2021","unstructured":"Camus V, Rossi C, Sesques P et al (2021) Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. Blood Adv 5:3862\u20133872. https:\/\/doi.org\/10.1182\/bloodadvances.2021004778","journal-title":"Blood Adv"},{"key":"3030_CR3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288232","author":"B Hess","year":"2025","unstructured":"Hess B, Moskowitz A, Davis JA et al (2025) Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2025.288232. (Epub ahead of print)","journal-title":"Haematologica"},{"key":"3030_CR4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Maeda LS et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408\u20131416. https:\/\/doi.org\/10.1056\/NEJMoa1214561","journal-title":"N Engl J Med"},{"key":"3030_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa1707447","volume":"108","author":"S Makita","year":"2017","unstructured":"Makita S, Yoshimura K, Tobinai K (2017) Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci 108:1109\u20131118. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"Cancer Sci"},{"key":"3030_CR6","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1002\/cam4.4820","volume":"11","author":"S Makita","year":"2022","unstructured":"Makita S, Yamamoto G, Maruyama D et al (2022) Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Cancer Med 11:4889\u20134899. https:\/\/doi.org\/10.1002\/cam4.4820","journal-title":"Cancer Med"},{"key":"3030_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s10147-025-02946-4","volume":"31","author":"T Ochi","year":"2026","unstructured":"Ochi T, Makita S, Hiratsuka A et al (2026) Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed\/refractory large B cell lymphoma in Japan. Int J Clin Oncol 31:428\u2013435. https:\/\/doi.org\/10.1007\/s10147-025-02946-4","journal-title":"Int J Clin Oncol"},{"key":"3030_CR8","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"3030_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (Transcend NHL 001): a multicentre seamless design study. Lancet 396:839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"key":"3030_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10147-021-020334","volume":"27","author":"K Kato","year":"2022","unstructured":"Kato K, Makita S, Goto H et al (2022) Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. Int J Clin Oncol 27:213\u2013223. https:\/\/doi.org\/10.1007\/s10147-021-020334","journal-title":"Int J Clin Oncol"},{"key":"3030_CR11","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J et al (2022) Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399:2294\u20132308. https:\/\/doi.org\/10.1016\/S0140-6736(22)00662-6","journal-title":"Lancet"},{"key":"3030_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA et al (2022) Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 386:640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"key":"3030_CR13","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1182\/bloodadvances.2021004880","volume":"5","author":"JL Crombie","year":"2021","unstructured":"Crombie JL, Nastoupil LJ, Redd R et al (2021) Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv 5:3563\u20133567. https:\/\/doi.org\/10.1182\/bloodadvances.2021004880","journal-title":"Blood Adv"},{"key":"3030_CR14","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1182\/bloodadvances.2023011203","volume":"7","author":"ML Schubert","year":"2023","unstructured":"Schubert ML, Bethge WA, Ayuk FA et al (2023) Outcomes of Axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA\/DRST registry study. Blood Adv 7:6191\u20136195. https:\/\/doi.org\/10.1182\/bloodadvances.2023011203","journal-title":"Blood Adv"},{"key":"3030_CR15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41375-024-02213-x","volume":"38","author":"A Chiappella","year":"2024","unstructured":"Chiappella A, Casadei B, Chiusolo P et al (2024) Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia 38:1107\u20131114. https:\/\/doi.org\/10.1038\/s41375-024-02213-x","journal-title":"Leukemia"},{"key":"3030_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70091","volume":"9","author":"J Galtier","year":"2025","unstructured":"Galtier J, Mesguich C, Sesques P et al (2025) Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry. Hemasphere 9:e70091. https:\/\/doi.org\/10.1002\/hem3.70091","journal-title":"Hemasphere"},{"key":"3030_CR17","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/ajh.70033","volume":"100","author":"J Gauthier","year":"2025","unstructured":"Gauthier J, Ahn KW, Patel J et al (2025) CD19 CAR T-cell therapy for primary mediastinal large B-cell lymphoma: a CIBMTR analysis. Am J Hematol 100:1792\u20131802. https:\/\/doi.org\/10.1002\/ajh.70033","journal-title":"Am J Hematol"},{"key":"3030_CR18","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1200\/JCO.19.01389","volume":"37","author":"P Armand","year":"2019","unstructured":"Armand P, Rodig S, Melnichenko V et al (2019) Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol 37:3291\u20133299. https:\/\/doi.org\/10.1200\/JCO.19.01389","journal-title":"J Clin Oncol"},{"key":"3030_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/10428194.2022.2136956","volume":"64","author":"J Kuruvilla","year":"2023","unstructured":"Kuruvilla J, Armand P, Hamadani M et al (2023) Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Leuk Lymphoma 64:130\u2013139. https:\/\/doi.org\/10.1080\/10428194.2022.2136956","journal-title":"Leuk Lymphoma"},{"key":"3030_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood.2022019340","volume":"142","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Thieblemont C, Melnichenko V et al (2023) Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood 142:141\u2013145. https:\/\/doi.org\/10.1182\/blood.2022019340","journal-title":"Blood"},{"key":"3030_CR21","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s10147-024-02627-8","volume":"29","author":"K Kato","year":"2024","unstructured":"Kato K, Nakamura S, Wakana A et al (2024) Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 study. Int J Clin Oncol 29:1977\u20131983. https:\/\/doi.org\/10.1007\/s10147-024-02627-8","journal-title":"Int J Clin Oncol"},{"key":"3030_CR22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO et al (2014) Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging 41:1113\u20131122. https:\/\/doi.org\/10.1007\/s00259-014-2705-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3030_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"3030_CR24","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra AJ et al (2019) Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant 25:2305\u20132321. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.015","journal-title":"Biol Blood Marrow Transplant"},{"key":"3030_CR25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp MS, van Meerten T, Houot R et al (2021) Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 195:388\u2013398. https:\/\/doi.org\/10.1111\/bjh.17673","journal-title":"Br J Haematol"},{"key":"3030_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"3030_CR27","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/10428190802108870","volume":"49","author":"J Kuruvilla","year":"2008","unstructured":"Kuruvilla J, Pintilie M, Tsang R et al (2008) Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma 49:1329\u20131336. https:\/\/doi.org\/10.1080\/10428190802108870","journal-title":"Leuk Lymphoma"},{"key":"3030_CR28","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.bbmt.2018.06.009","volume":"24","author":"S Vardhana","year":"2018","unstructured":"Vardhana S, Hamlin PA, Yang J et al (2018) Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant 24:2133\u20132138. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.009","journal-title":"Biol Blood Marrow Transplant"},{"key":"3030_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.101","volume":"5","author":"T Aoki","year":"2015","unstructured":"Aoki T, Shimada K, Suzuki R et al (2015) High-dose chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J 5:e372. https:\/\/doi.org\/10.1038\/bcj.2015.101","journal-title":"Blood Cancer J"},{"key":"3030_CR30","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","volume":"123","author":"DD Twa","year":"2014","unstructured":"Twa DD, Chan FC, Ben-Neriah S et al (2014) Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123:2062\u20132065. https:\/\/doi.org\/10.1182\/blood-2013-10-535443","journal-title":"Blood"},{"key":"3030_CR31","doi-asserted-by":"publisher","first-page":"14780","DOI":"10.3390\/ijms241914780","volume":"24","author":"MA P\u00e9rez-Moreno","year":"2023","unstructured":"P\u00e9rez-Moreno MA, Ciudad-Guti\u00e9rrez P, Jaramillo-Ruiz D et al (2023) Combined or sequential treatment with immune checkpoint inhibitors and CAR-T cell therapies for the management of haematological malignancies: a systematic review. Int J Mol Sci 24:14780. https:\/\/doi.org\/10.3390\/ijms241914780","journal-title":"Int J Mol Sci"},{"key":"3030_CR32","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1182\/bloodadvances.2023010016","volume":"7","author":"A Major","year":"2023","unstructured":"Major A, Yu J, Shukla N et al (2023) Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv 7:4528\u20134538. https:\/\/doi.org\/10.1182\/bloodadvances.2023010016","journal-title":"Blood Adv"},{"key":"3030_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","volume":"8","author":"AV Hirayama","year":"2024","unstructured":"Hirayama AV, Kimble EL, Wright JH et al (2024) Timing of anti\u2013PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv 8:453\u2013467. https:\/\/doi.org\/10.1182\/bloodadvances.2023011287","journal-title":"Blood Adv"},{"key":"3030_CR34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","volume":"9","author":"A Looka","year":"2025","unstructured":"Looka A, Qualls DA, Matthews D et al (2025) A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. Blood Adv 9:455\u2013462. https:\/\/doi.org\/10.1182\/bloodadvances.2024012992","journal-title":"Blood Adv"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03030-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03030-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03030-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:19:29Z","timestamp":1782407969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03030-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3030"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03030-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM received honoraria for lectures from Chugai Pharmaceutical Co., Bristol Myers Squibb, Gilead Sciences, and Genmab. HM received research funding from AbbVie. SF received research funding from LOXO Oncology, AbbVie, Chugai Pharmaceutical Co., and Mitsubishi Tanabe Pharma Co. WM received research funding from Genmab, Nippon Shinyaku Co., and Ono Pharmaceutical Co. KI received research funding from AstraZeneca, AbbVie, Incyte Biosciences Japan, Bristol Myers Squibb, Novartis, Daiichi Sankyo Co., Chugai Pharmaceutical Co., Beigene, Genmab, LOXO Oncology, and Regeneron. All other authors declare no conflicts of interest associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}